A Phase 2 trial evaluating XmAb942 (Xtend anti-TL1A) in participants with ulcerative colitis
Latest Information Update: 04 Mar 2025
At a glance
- Drugs XmAb 942 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms XENITH-UC
Most Recent Events
- 04 Mar 2025 New trial record
- 27 Feb 2025 According to Xencor media release, the company plans to initiate this trial in the second half of 2025